Medikit (7749) Q2 2027 earnings summary

Executive summary

• H1 FY2027 net sales rose 6.9% YoY to ¥12,740.5m; operating profit increased 10.6% to ¥2,480.8m and net profit rose 8.4% to ¥1,464.5m.

• Comprehensive income reached ¥1,773.1m, up from ¥1,210.8m YoY, supported by gains in available-for-sale securities.

Financial highlights

• Gross profit was ¥4,843.5m versus ¥4,580.1m; SG&A was ¥2,362.7m versus ¥2,337.1m for the six months ended September 30, 2026.

• Ordinary profit increased 9.6% YoY to ¥2,557.7m; profit attributable to owners of parent rose 8.4% to ¥1,464.5m.

• Operating cash flow was ¥1,363.4m, down from ¥2,472.2m YoY; cash and cash equivalents ended the period at ¥15,775.2m.

Outlook and guidance

• FY2027 forecast: net sales ¥25,800m (+8.5% YoY), operating profit ¥4,300m (+0.6%), ordinary profit ¥4,400m (-1.9%), and net profit ¥2,850m (-5.2%).

• Forecast basic EPS is ¥196.73; full-year forecast unchanged from the latest announcement.

• Forecast dividends are ¥50 per share at both interim and year-end, totaling ¥100 per share; dividend forecast unchanged.